Product details
Background：IL-17A encodes a Proinflammatory cytokine protein that, together with IL-17A, participates in immune responses and inflammation. The IL-17 family also includes members such as IL17F and IL17C, but IL-17A is often regarded as one of the core driver molecules of this pathway. Il-17a activates downstream NF-κb, MAPK, C/EBP, and other signaling pathways by binding to the IL-17R (including subtypes of IL-17RA, IL-17RC, etc.) complex, and the IL-17R/IL-17R/IL-17R/IL-17R/IL-17R/IL-17R/IL-17R/IL-17R/IL-17R/IL-17R It induces the expression of a variety of chemokines, cytokines (such as IL-6, IL-8, GM-CSF) and chemokine proteins, promoting neutrophil recruitment and amplification of inflammation. Ixekizumab is a fully humanized monoclonal antibody (MAB) that targets IL-17A. By specifically binding to IL-17A, the interaction between IL-17A and Il-17 receptor is blocked, thereby inhibiting the expression of downstream pro-inflammatory factors, chemokines and inflammatory cells, and reducing inflammatory response and immune damage.
